{"title":"程序性死亡-1 抑制剂单药治疗后侵犯超朱砂边缘的皮肤鳞状细胞癌的假性进展。","authors":"Sach Thakker, Naghmeh Yousefzadeh, Jafar Al-Mondhiry","doi":"10.1002/ski2.400","DOIUrl":null,"url":null,"abstract":"<p><p>A 55-year-old woman with a moderately differentiated cutaneous squamous cell carcinoma (cSCC) of the upper lip experienced initial tumour growth and new lymphadenopathy after starting immunotherapy with Cemiplimab, but achieved complete remission with no adverse events after five infusions. This case underscores the potential of immunotherapy for cSCC in sensitive head and neck areas and illustrates the phenomenon of pseudoprogression, where apparent tumour growth can occur before clinical improvement.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 4","pages":"e400"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297434/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy.\",\"authors\":\"Sach Thakker, Naghmeh Yousefzadeh, Jafar Al-Mondhiry\",\"doi\":\"10.1002/ski2.400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A 55-year-old woman with a moderately differentiated cutaneous squamous cell carcinoma (cSCC) of the upper lip experienced initial tumour growth and new lymphadenopathy after starting immunotherapy with Cemiplimab, but achieved complete remission with no adverse events after five infusions. This case underscores the potential of immunotherapy for cSCC in sensitive head and neck areas and illustrates the phenomenon of pseudoprogression, where apparent tumour growth can occur before clinical improvement.</p>\",\"PeriodicalId\":74804,\"journal\":{\"name\":\"Skin health and disease\",\"volume\":\"4 4\",\"pages\":\"e400\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297434/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin health and disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ski2.400\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ski2.400","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy.
A 55-year-old woman with a moderately differentiated cutaneous squamous cell carcinoma (cSCC) of the upper lip experienced initial tumour growth and new lymphadenopathy after starting immunotherapy with Cemiplimab, but achieved complete remission with no adverse events after five infusions. This case underscores the potential of immunotherapy for cSCC in sensitive head and neck areas and illustrates the phenomenon of pseudoprogression, where apparent tumour growth can occur before clinical improvement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
